Teva Pharmaceutical Industries (TEVA) Goldman Sachs 45th Annual Global Healthcare Conference summary

Strategic transformation and capital allocation

• Pivot to Growth strategy centers on four pillars: innovation, sustainable generics, business focus, and capital allocation, with a clear plan for 2023-2030 growth.

• Capital has been ruthlessly reallocated, reducing generics pipeline coverage from 85-90% to 65% to free resources for innovation.

• Sales and marketing resources have shifted from older products to key growth drivers like Austedo, Ajovy, and UZEDY.

• Performance is driven by clarity of focus, capability building, and disciplined measurement.

• The company is recognized for improved execution in both innovative and generics businesses.

Financial targets and investment approach

• Returned to revenue growth after several years of decline, with a target of 30% EBIT margins by 2027.

• Investment in R&D and sales is expected to yield non-linear margin improvement, with acceleration as new products launch and generics stabilize.

• Focused on balancing near-term investment with long-term profitability, emphasizing execution and future growth.

Pipeline development and business development

• Pipeline is described as low in quantity but high in quality, with key assets including olanzapine, ICS-SABA, TL1A, IL-15, and a PD-1/IL-2 drug for MS.

• Actively seeking in-licensing opportunities, especially late-stage assets, to supplement organic pipeline growth.

• Upcoming launches expected in 2026-2027, with no significant patent cliffs anticipated.